title: Use of inhaled nitric oxide in preterm infants.
abstract: Nitric oxide, an important signaling molecule with multiple regulatory effects throughout the body, is an important tool for the treatment of full-term and late-preterm infants with persistent pulmonary hypertension of the newborn and hypoxemic respiratory failure. Several randomized controlled trials have evaluated its role in the management of preterm infants ≤ 34 weeks' gestational age with varying results. The purpose of this clinical report is to summarize the existing evidence for the use of inhaled nitric oxide in preterm infants and provide guidance regarding its use in this population.
authors.forename: Praveen
authors.initials: P
authors.lastname: Kumar
mesh_terms: D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000191:economics; D009569:Nitric Oxide / Q000191:economics / Q000627:therapeutic use*; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy* / Q000191:economics; D012131:Respiratory Insufficiency / Q000188:drug therapy* / Q000191:economics; D016896:Treatment Outcome; D014481:United States
chemical_list: D001993:Bronchodilator Agents; D009569:Nitric Oxide
keywords: bronchopulmonary dysplasia; hypoxic respiratory failure; inhaled nitric oxide; preterm infants